Please login to the form below

Not currently logged in
Email:
Password:

BMS' profit down, Lilly's up

Bristol-Myers Squibb has reported a drop in Q2 profit while Eli Lilly has announced a net income increase of 16 per cent for the quarter

Bristol-Myers Squibb (BMS) has reported a drop in second-quarter profit that the company attributes to the 2009 spin-off of its nutritionals unit. Profit was down by about 6 per cent compared to last year's second quarter, coming in at $927m, or 53 cents per share.

Revenue was up slightly, coming in at $4.77bn for the quarter, compared to $4.67bn in 2009's second quarter.

Eli Lilly and Company's second-quarter net income was up 16 per cent to $1.35bn, or $1.22 per share, compared to $1.16bn, or $1.06 per share, in the second quarter of 2009. Revenue was up 9 per cent to $5.75bn.

However, Lilly's good news was tempered by the fact that the numbers largely reflect robust sales of drugs that are due to go off patent in the coming years.

For example, antipsychotic Zyprexa (olanzapine) sales were up 5 per cent to $1.26bn and antidepressant Cymbalta (duloxetine) sales were up 17 per cent to $867.7m. Zyprexa is due to lose US patent protection next year, while Cymbalta will go off patent in 2013.

22nd July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics